Guillain-Barré Syndrome After Receiving the First Dose of Oxford– AstraZeneca SARS-CoV-2 Vaccine
Acta Medica Iranica
; 60(6):384-386, 2022.
Article
in English
| EMBASE | ID: covidwho-2033506
ABSTRACT
Safety monitoring of COVID-19 vaccination is paramount of importance. There are limited reports of Guillain-Barré syndrome (GBS) associated with the COVID-19 vaccination. The present study reported a case of GBS following the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine. A 32-year-old man presented a history of progressive descending weakness and autonomic features within a month after receiving the Oxford-AstraZeneca SARS-CoV-2 vaccine. The neurological examination was consistent with acute polyneuropathy. The para-clinical investigations were in favor of acute demyelinating polyneuropathy. The patient was diagnosed with GBS, and IVIG was initiated as an acute treatment, which led to significant clinical recovery. We reported a case of GBS after receiving the Oxford-AstraZeneca vaccine. However, our findings dose not conclude a causal association between GBS and COVID-19 vaccination.
human immunoglobulin; labetalol; protein; vaxzevria; action potential; adult; article; blood pressure; case report; cerebrospinal fluid analysis; clinical article; coronavirus disease 2019; demyelinating neuropathy; electromyography; emergency ward; Guillain Barre syndrome; hemodynamics; human; intensive care unit; male; medical research council score; nerve conduction; neurologic examination; paresis; pinprick test; polyradiculoneuropathy; rehabilitation care; tachycardia; tendon reflex; tibial nerve; vaccination; vibration sensation
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Acta Medica Iranica
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS